Drug Therapy, Combination

"Drug Therapy, Combination" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Therapy with two or more separate preparations given for a combined effect.

Descriptor ID	D004359
MeSH Number(s)	E02.319.310
Concept/Terms	Drug Therapy, Combination Drug Therapy, Combination Combination Chemotherapy Drug Polytherapy Drug Polytherapies Polytherapies, Drug Polytherapy, Drug Therapy, Combination Drug Chemotherapy, Combination Chemotherapies, Combination Combination Chemotherapies Combination Drug Therapy Combination Drug Therapies Drug Therapies, Combination Therapies, Combination Drug Polychemotherapy Polychemotherapy Polychemotherapies

Below are MeSH descriptors whose meaning is more general than "Drug Therapy, Combination".

Analytical, Diagnostic and Therapeutic Techniques and Equipment [E]
Therapeutics [E02]
Drug Therapy [E02.319]
Drug Therapy, Combination [E02.319.310]

Below are MeSH descriptors whose meaning is more specific than "Drug Therapy, Combination".

Drug Therapy, Combination
Antineoplastic Combined Chemotherapy Protocols
Antiretroviral Therapy, Highly Active

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Drug Therapy, Combination" by people in this website by year, and whether "Drug Therapy, Combination" was a major or minor topic of these publications.

Bar chart showing 398 publications over 31 distinct years, with a maximum of 26 publications in 2009

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	0	2	2
1997	2	5	7
1998	2	5	7
1999	0	3	3
2000	0	7	7
2001	0	8	8
2002	0	10	10
2003	3	15	18
2004	0	10	10
2005	0	11	11
2006	1	15	16
2007	0	10	10
2008	1	15	16
2009	0	26	26
2010	1	21	22
2011	1	20	21
2012	1	18	19
2013	0	22	22
2014	0	16	16
2015	1	20	21
2016	0	18	18
2017	1	16	17
2018	1	20	21
2019	0	16	16
2020	1	18	19
2021	0	8	8
2022	0	7	7
2023	0	4	4
2024	2	6	8
2025	0	7	7
2026	0	1	1

Below are the most recent publications written about "Drug Therapy, Combination" by people in Profiles.

Bendel RA, Alexopoulos GS, Marino P, Meyers BS, Mulsant BH, Neufeld NH, Rothschild AJ, Voineskos AN, Whyte EM, Flint AJ, Bingham KS. Effect of continuation treatment on health-related quality of life in remitted psychotic depression. J Affect Disord. 2026 Oct 15; 411:122015.

View in: PubMed
Patel M, Marshall J, Martinez FJ, Mushunje A, Bowen K, Jenkins M. Frequent productive cough in COPD relates to exacerbation risk and treatment benefit from budesonide/glycopyrrolate/formoterol fumarate: a post hoc analysis of KRONOS. Respir Med. 2025 12; 250:108499.

View in: PubMed
Cazzola M, Page CP, Calzetta L, Martinez FJ, Rogliani P, Matera MG. Ensifentrine Plus a Long-Acting Muscarinic Antagonist in COPD: A Trifunctional Dual Bronchodilation Perspective. Drugs. 2025 Sep; 85(9):1099-1107.

View in: PubMed
Curtis KL, Piraccini BM, Starace M, Rapparini L, Richert B, Rubin AI, Jellinek NJ, Tosti A, Di Chiacchio NG, Di Chiacchio N, Iorizzo M, Grover C, Hinshaw MA, Vlahovic TC, Bellet JS, Rigopoulos D, Lipner SR. Diagnosis and management of yellow nail syndrome: An international multi-institutional retrospective cohort study of 111 cases by an expert panel. J Am Acad Dermatol. 2025 11; 93(5):1268-1276.

View in: PubMed
Sciurba FC, Criner GJ, Christenson SA, Martinez FJ, Papi A, Roche N, Bourbeau J, Korn S, Bafadhel M, Han MK, Kolterer S, Miller K, Mouneimne D, Fletcher J, Mayer B, Min J, Pavord ID. Mepolizumab to Prevent Exacerbations of COPD with an Eosinophilic Phenotype. N Engl J Med. 2025 May 01; 392(17):1710-1720.

View in: PubMed
Carter E, Banerjee S, Alexopoulos GS, Bingham KS, Marino P, Meyers BS, Mulsant BH, Neufeld NH, Rothschild AJ, Voineskos AN, Whyte EM, Flint AJ. Prediction of remission of pharmacologically treated psychotic depression: A machine learning approach. J Affect Disord. 2025 Jul 15; 381:291-297.

View in: PubMed
Masri A, Maron MS, Abraham TP, Nassif ME, Barriales-Villa R, Bilen O, Coats CJ, Elliott P, Garcia-Pavia P, Massera D, Olivotto I, Oreziak A, Owens AT, Saberi S, Solomon SD, Tower-Rader A, Heitner SB, Jacoby DL, Melloni C, Wei J, Sherrid MV. Concomitant Aficamten and Disopyramide in Symptomatic Obstructive Hypertrophic Cardiomyopathy. JACC Heart Fail. 2026 Feb; 14(2):102441.

View in: PubMed
Singh D, Martinez FJ, Hurst JR, Han MK, Gale CP, Fredriksson M, Kisielewicz D, Mushunje A, Movitz C, Ojili N, Parikh H, Arya N, Bowen K, Patel M. Effect of Triple Therapy on Cardiovascular and Severe Cardiopulmonary Events in Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis of a Randomized, Double-Blind, Phase 3 Clinical Trial (ETHOS). Am J Respir Crit Care Med. 2025 02; 211(2):205-214.

View in: PubMed
Harrold LR, Bingham CO, Pope JE, O'Brien J, Moore PC, Roberts-Toler C, Yu M, Sweet LL, Shelbaya A, Masri KR. Effectiveness of tofacitinib versus tumor necrosis factor inhibitors and in those receiving tofacitinib as different lines of therapy in patients with rheumatoid arthritis: results from the United States CorEvitas Rheumatoid Arthritis Registry. Clin Rheumatol. 2025 Feb; 44(2):635-648.

View in: PubMed
Chaudhry IB, Husain MO, Khoso AB, Kiran T, Husain MI, Qurashi I, Rahman RU, Mehmood N, Drake R, Husain N, Deakin B. Beneficial adjunctive effects of the 5HT3 receptor antagonist ondansetron on symptoms, function and cognition in early phase schizophrenia in a double-blind, 2 ? 2 factorial design, randomised controlled comparison with simvastatin. J Psychopharmacol. 2024 Sep; 38(9):818-826.

View in: PubMed

People

Explore

Similar Concepts

Top Journals